MEN1-Associated Hypoparathyroidism After Parathyroidectomy: When First-Line Therapy Falls Short
This protocol addresses Multiple endocrine neoplasia type 1 (MEN1) in patients who develop hypoparathyroidism following parathyroidectomy for MEN1-related primary hyperparathyroidism — and specifically those in whom standard first-line management has not achieved adequate control.
Clinical Scenario
Post-surgical hypoparathyroidism is a recognised complication of parathyroidectomy in MEN1. First-line management follows established guidelines for sporadic hypoparathyroidism, targeting serum calcium in the lower half of, or just below, the normal reference range, with resolution of symptomatic hypocalcaemia and avoidance of hypercalciuria.
First-Line Failure Condition
When treatment with
calcium together with an active vitamin D analogue does not raise serum calcium to the lower half of, or just below, the normal reference range — or fails to resolve symptomatic hypocalcaemia and prevent hypercalciuria — escalation to a further step is indicated.
Next-Line Approach (Partial Overview)
In patients with inadequately controlled hypoparathyroidism, a
parathyroid hormone (PTH) therapy approach may be considered as the next step.
The full protocol — including specific agent selection, criteria, and monitoring — is available via the link below.
References
The management of hypoparathyroidism in MEN1 follows the same principles outlined in international guidelines for sporadic disease, and includes treatment with calcium and an active vitamin D analogue, with the goal of raising serum calcium to the lower half of the normal reference range or just below the normal reference range, and alleviating symptomatic hypocalcaemia, while avoiding hypercalciuria.
PTH therapy can also be considered in patients whose hypoparathyroidism is inadequately controlled with conventional therapy.
DOI: 10.1016/S2213-8587(25)00119-6
View source ↗